

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER P64075US0
		APPLICATION NO. (If known, see 37 CFR 1.5) 09 / 424244
INTERNATIONAL APPLICATION NO. PCT/EP98/06137	INTERNATIONAL FILING DATE 26 September 1998	PRIORITY DATE CLAIMED 27 September 1997
TITLE OF INVENTION A METHOD FOR IDENTIFYING ACTIVE SUBSTANCES		
APPLICANT(S) FOR DO/EO/US Andreas STRAUSS, Günther THUMM, Johannes POHLNER and Friedrich GÖTZ		

Applicant herein submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for Internatl. Preliminary Examination was made by the 19th month from earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the Internatl. Preliminary Examination report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

First Page of Publication

US APPLICATION NO. (if known, see 37 CFR 1.5) 09/424244		INTERNATIONAL APPLICATION NO. PCT/EP98/06137		ATTORNEY'S DOCKET NUMBER P64075US0	
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Internatl. prelim. examination fee paid to USPTO (37 CFR 1.492 (a) (1)) ... \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.492 (a) (2)) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ... \$760.00 Neither international preliminary examination fee (37 CFR 1.492 (a) (3)) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO) \$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.492 (a) (4)) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00 Search Report prepared by the EPO or JPO (37 CFR 1.492 (a) (5)) \$840.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS	PTO USE ONLY
				\$ 840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	14 - 20 =	-0-	x \$18.00	\$	
Independent Claims	1 - 3 =	-0-	x \$78.00	\$	
Multiple Dependent Claim(s) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 970.00	
Reduction by 1/2 for filing by small entity , if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 970.00	
Processing fee of \$130 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f))				\$	
TOTAL NATIONAL FEE =				\$ 970.00	
Fee of \$40.00 for recording the enclosed assignment (37 CFR 1.21(h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31).				\$	
TOTAL FEES ENCLOSED =				\$ 970.00	
				Amt. to be refunded:	\$
				Amt. charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>970.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>06-1358</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge my account any additional fees set forth in §1.492 during the pendency of this application, or credit any overpayment to Deposit Account No. <u>06-1358</u> . A duplicate copy of this sheet is enclosed.					
<div style="display: flex; justify-content: space-between;"> <div style="width: 60%;"> <p>SEND ALL CORRESPONDENCE TO: Jacobson, Price, Holman & Stern, PLLC 400 7th Street, N.W., Suite 600 Washington, DC 20004 202-638-6666 CUSTOMER NUMBER: 00136</p> </div> <div style="width: 35%; text-align: right;"> <p>By <u>William E. Player</u> William E. Player Reg. No. 31,409</p> </div> </div>					

09/424244

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Andreas STRAUSS et al. 420 Rec'd PCT/PTO 29 NOV 1999
Serial No.: New
Filed: November 29, 1999
For: A METHOD FOR IDENTIFYING ACTIVE SUBSTANCES

PRELIMINARY AMENDMENT TO LESSEN FEES

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS

Claim 3, line 1, delete "claims 1 and/or 2",
insert --claim 1--;
Claim 4, line 1, delete "at least one of claims 1 to 3",
insert --claim 1--;
Claim 5, line 1, delete "at least one of claims 1 to 4",
insert --claim 1--;
Claim 8, line 1, delete "at least one of claims 6 to 7",
insert --claim 6--;
Claim 9, line 1, delete "to 8";
Claim 10, line 1, delete "at least one of claims 1 to 9",
insert --claim 1--;
Claim 11, line 1, delete "at least one of claims 1 to 10",
insert --claim 1--;
Claim 12, line 1, delete "at least one of claims 1 to 11",
insert --claim 1--;
Claim 13, line 1, delete "at least one of claims 1 to 12",
insert --claim 1--;
Claim 14, line 1, delete "at least one of claims 1 to 13",
insert --claim 1--.


REMARKS

The foregoing Preliminary Amendment is requested in order to delete the multiple dependent claims and avoid paying the multiple dependent claims fee.

Early action on the merits is respectfully requested.

Respectfully submitted,

JACOBSON, PRICE, HOLMAN & STERN, PLLC

By 
William E. Player
Reg. No. 31,409

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666

Date: November 29, 1999
Atty. Docket: P64075US0
WEP:crj

420 Rec'd PCT/PTO 29 NOV 1999

SMB

A Method for Identifying Active Substances

The present invention relates to a method for identifying active substances which affect the covalent bonding of polypeptides to the surface of Gram-positive bacteria.

In view of the increased occurrence of antibiotic-resistant strains, infections in humans caused by Gram-positive bacteria are an increasing therapeutic challenge. The pathogenesis of these organisms is associated with a wide variety of bacterial surface proteins. Thus, pathogenicity factors anchored to the cell wall are known which promote bacterial adhesion by the binding to extracellular matrix components of the host tissues, such as collagen. Other factors bind serum components, such as IgG, and thus conceal the authentic bacterial surface from the host's immune system. Therefore, selective inhibition of the binding reaction of these proteins to the bacterial cell wall is of great medical interest.

Schneewind et al. (Cell, Vol. 70, p. 267-281, 1992) have studied the anchoring mechanism of protein A in the cell wall of *Staphylococci*. Protein A belongs to a growing class of surface proteins of Gram-positive bacteria which are characterized by a succession of the characteristic sequence motif LPXTG, followed by a group of 15-22 hydrophobic amino acids, and a C-terminal group of 5-12 charged amino acids. The conservation of these elements is considered an indication of a common export mechanism of these proteins in different Gram-positive species. In order to establish the localization of protein A (discrimination between protein A anchored in the cell wall and secreted

protein A) in *S. aureus*, the authors employ radioactive labeling methods. The importance of the above mentioned sequence elements to cell wall anchoring is supported by using hybrid proteins and through mutagenesis of the LPXTG motif and of the C terminus. However, Schneewind et al. are concerned neither with enzymes which might catalyze the anchoring of the surface proteins, nor with their inhibition.

The cell wall anchoring elements in surface proteins of Gram-positive bacteria are also the subject of another article by Schneewind et al. (EMBO J., Vol. 12, p. 4803-4811, 1993). It is shown that enterotoxin B, a protein normally secreted into the medium, can be anchored in the *Staphylococcus* cell wall through C-terminal fusion to the protein A anchoring signal. The results support the hypothesis that the cell wall sorting is accompanied by a proteolytic cleavage of the polypeptide chain at the C terminus. Presumably, the LPXTG motif is the site of such cleavage and covalent binding to the cell wall while the charged sequence segment serves as a retention signal during the cell wall sorting. The relevance of the geometrical length of the hydrophobic domain, which is dependent on the folding properties, is confirmed by experiments.

An article by Samuelson et al. (J. Bacteriol., Vol. 177, No. 6, p. 1470-1476, 1995) is concerned with the cellular surface display of recombinant proteins on *Staphylococcus carnosus*. The surface display of the malaria peptide M3 is effected using the promoter, secretion signal and propeptide region of the lipase gene of *S. hyicus* and the cell wall anchoring regions of protein A of *S. aureus*. The hybrid protein structure further includes a serum albumin binding protein which serves for the detection of the recombinant surface-anchored proteins in a colorimetric sandwich assay. Further detection methods comprise immunogold electron microscopy, immunofluorescence assays and fluorescence-activated cell sorting (FACS). Samuelson et al.

are not concerned with the exact molecular mechanisms of cell wall anchoring either.

The structure of the cell wall anchor of the surface proteins in *Staphylococcus aureus* is the subject of a report by Schneewind et al. (Science, Vol. 268, p. 103-106, 1995). The authors use a combination of molecular-biological and mass-spectrometric techniques and are able to show that after cleavage of the surface protein between threonine and glycine of the conserved LPXTG motif, the carboxy group of threonine is covalently bonded via transpeptidization to the murein sacculus with the free amino group of the cell wall pentaglycine. However, Schneewind et al. also fail to identify or characterize the protein believed to be responsible for proteolysis and transpeptidization, the so-called sortase.

Strauß and Götz (Molecular Microbiology, Vol. 21, p. 491-500, 1996) are concerned with the in vivo immobilization of enzymatically active polypeptides on the cellular surface of *Staphylococcus carnosus*. They have constructed a hybrid protein which consists of *Staphylococcus hyicus* lipase and the C-terminal region of *Staphylococcus aureus* fibronectin binding protein B (FnBFPB). To study the cell wall association of the prolipase, or the pro-LipFnBFPB hybrid, the authors use a prolipase-specific antiserum in an immunofluorescence assay and immunoblotting. Further examinations have demonstrated that a distance of about 90 amino acids between the C terminus of the enzyme and the cell wall sorting signal is evidently indispensable to an efficient folding of the lipase into its active conformation. The influence of greater distances has been examined on fusions of proLip and the C-terminal region of *S. aureus* protein A (proLipSPA, spacer with 165 amino acids) and *S. aureus* fibronectin binding protein A (proLipFnBPA, spacer with 223 amino acids). Additional experiments were performed with *E. coli* β -lactamase as the reporter molecule.

WO-A-97/08553 describes a method for the stable non-covalent display of proteins, peptides and other substances on the surface of Gram-positive bacteria. Comparative studies between the non-covalent display process and the covalent display process, which has been described in more detail above, were performed. When the C-terminal sorting signal of protein A, which results in covalent display, was replaced by the cell wall targeting signal of lysostaphin (SPA_{CWT}), an essentially unchanged binding intensity of FITC-labeled IgG to the *Staphylococcus* surface could be observed.

US-A-5,616,686 discloses a polypeptide consisting of about 6 to 20 amino acids which contains as an integral part a peptide construct which is responsible for the anchoring of virulence-determining proteins on the surface of Gram-positive bacteria. In particular, this construct is characterized by containing the amino acids L, P, T and G at positions 1, 2, 4 and 5, respectively, of the amino acid sequence. Due to the homology of these peptides with the sequences of the virulence determinants in the wild type surface proteins, the former presumably react with enzymes involved in anchoring. The result is that the virulence determinants of the bacteria cannot be anchored or can be anchored only to a lesser extent, and thus the progress of the infection is prevented. However, the enzyme or enzymes involved in surface anchoring are not characterized in this patent specification either.

WO-A-93/18163 is concerned with the provision of fusion proteins which contain at least the anchoring region of Gram-positive surface proteins as well as varying proteins, polypeptides or peptides, especially those having a therapeutic effect in humans and animals. The anchoring region comprises an LPSTGE segment, a spacer segment of the sequence TAN, a hydrophobic segment consisting of 20 amino acids, and a charged segment with the sequence KRKEEN.

It is desirable to provide a method which allows the identification of active substances which directly or indirectly affect the covalent bonding of polypeptides to the surface of Gram-positive bacteria.

Surprisingly, this object is achieved by the method of the present invention.

"Polypeptides" within the meaning of the invention means polymers usually composed of at least 20 amino acids and also comprises proteins, in particular. The amino acids are represented by the one-letter code where X represents an arbitrary amino acid.

In the following, the basis of a preferred embodiment of the method according to the invention shall first be set forth before the method for the identification of active substances is dealt with in detail.

In a preferred embodiment, the method according to the invention is to be considered an enzymatic reporter assay which detects the effect of substances on bacterial factors (targets) which directly or indirectly participate in the LPXTG-motif-dependent C-terminal anchoring of polypeptides to the surface of Gram-positive bacteria. Among the large number of factors and processes which may have an effect on this process, the present invention preferably aims at those enzymatic steps which take place after the beginning of the translocation of the cellular surface polypeptides over the cytoplasmic membrane. In addition, the method according to the invention in part covers enzymatic and other targets which participate in the biosynthesis of cell wall murein. From the phenotypical characteristics of the cells used in the respective method, potentially active substances can be assigned to particular groups of targets.

In a particularly preferred embodiment of the method according to the invention, the cellular and molecular basis of the reporter assay is a recombinant *Staphylococcus carnosus* clone which contains a selectable expression plasmid with an inducible reporter gene fusion. The gene fusion codes for a hybrid polypeptide consisting of an N-terminal signal peptide, a precursor protein of *Staphylococcus hyicus* lipase and a C-terminal portion of the fibronectin binding protein B (FnBPB) from *Staphylococcus aureus*. After being produced in the cytoplasm, the hybrid polypeptide is transported through the bacterial cell membrane due to its N-terminal signal structures, and processed at the amino terminus by a signal peptidase. Further, a cleavage in the C-terminal LPXTG recognition motif is performed, and the remaining hybrid protein is covalently linked to the murein. It has been experimentally established that different lengths of the FnBPB portion influence the building of enzymatic activity of the lipase fusions differently. One construct was identified which exhibited no lipase activity in its cellular-surface bound form (coded by plasmid pTX30A82). However, if the corresponding fusion was released from the bacterial surface by treatment with lysostaphin after having been covalently anchored, the full lipase activity was achieved. Within the scope of the present invention, it has been recognized for the first time that interferences with the cell wall anchoring of the lipase function result in a release of the fusion with a concomitant occurrence of lipase activity in the culture supernatants in the assay clone in question. As possible targets, various cellular factors may be considered which can be essentially divided into two groups according to their growth behavior.

One target or group of targets is the enzyme or enzyme complex designated as sortase which effects the carboxy-terminal cleavage of relevant polypeptides in the LPXTG motif and their subsequent covalent bonding to peptide components of the cell wall murein, such as interpeptide bridges, especially pentagly-

cine units, on the surface of the bacteria. Although the inhibition of these functions presumably leads to the release of surface-bound factors and thus probably to the attenuation of pathogenic bacteria, it probably does not lead to significant impairments of the viability and dividability of the bacteria. A characteristic phenotypical feature of this group of targets in the assay procedure is the release of lipase activity into the assay medium while the growth behavior of the bacteria is more or less unaffected. In contrast, the impairment of a target or group of targets having an essential function in murein synthesis results in massive changes in the viability and dividability of the bacteria which are phenotypically detectable.

To demonstrate the potential suitability of the method according to the invention for the examination of the target "sortase", two different inhibition/mutation scenarios have been simulated using hybrid proteins which have been genetically engineered in a well-aimed manner (see Example 1 and Figures 1 and 2).

After induction of the xylose promoter, *S. carnosus*/pTX30Δ82.mem produces a hybrid protein consisting of *S. hyicus* prolipase and the C-terminal fragment of *S. aureus* fibronectin binding protein B (FnBFB) wherein the LPXTG motif, which is important to the anchoring to the cell wall, has been exchanged for the sequence ISQAS (Figure 1). In other embodiments, however, it may also be exchanged for any other sequence which preferably consists of 5 amino acids. In a further embodiment, LPXTG substitution is not necessary for the mem phenotype, but a complete deletion of the LPXTG motif may also be considered. Thus, the specific cleavage at the LPXTG motif and hence the covalent binding to the murein sacculus do not take place. Surprisingly, it could be shown that the hydrophobic anchoring sequence which is thus retained at the carboxy terminus of the fusion is evidently not sufficient to anchor the lipase stably and espe-

cially in an inactive form in the cell coat and thus at the cellular surface. The lipase activity is quantitatively released from the bacterial surface into the culture medium. Thus, this clone simulates the inhibition of the cleavage reaction by sortase, an essential step which precedes the covalent bonding of the N-terminal cleavage product to the murein at the cell wall.

After induction of the xylose promoter, *S. carnosus*/pTX30Δ82.sec produces a hybrid protein consisting of *S. hyicus* prolipase and a C-terminal fragment of *S. aureus* fibronectin binding protein B (FnBPB) which ends with the motif LPETGG (Figure 1). This clone simulates the inhibition of the (covalent) bonding reaction between the lipase hybrid protein to be anchored, which has already been processed at the C terminus, and the cell wall. This clone quantitatively releases the lipase hybrid protein in the culture supernatant in an active conformation.

According to the invention, the identification of active substances which affect the covalent bonding of polypeptides to the surface of Gram-positive bacteria is effected by a method comprising the following steps:

- a) providing a sample of Gram-positive bacteria which contain or produce at least one enzymatic reporter substance which is or can become covalently bonded to the surface of the Gram-positive bacteria, said at least one reporter substance having a different enzymatic activity when not covalently bonded to the surface of the Gram-positive bacteria from that exhibited when it is covalently bonded to the surface of the Gram-positive bacteria;
- b) contacting the sample with a possible active substance;
- c) assaying the enzymatic activity of the reporter substance of the Gram-positive bacteria of the sample.

Within the meaning of the method according to the invention, "when not covalently bonded" includes both non-covalent bonding to the surface of the Gram-positive bacteria and complete release.

Said assaying of the enzymatic activity of the reporter substance of the Gram-positive bacteria of the sample can preferably be done by comparison with at least one reference sample which has not been contacted with the active substance, and/or at least one reference sample in which the reporter substance is non-covalently bonded to the surface of Gram-positive bacteria, and/or at least one reference sample in which the reporter substance is covalently bonded to the surface of the Gram-positive bacteria, and/or at least one reference sample in which the reporter substance is present without covalent bonding to the surface of the Gram-positive bacteria.

The method according to the invention advantageously allows the selective identification of such active substances as directly or indirectly affect the covalent bonding of polypeptides to the surface of Gram-positive bacteria. As set forth above, the putative process of surface anchoring comprises two specific steps:

- a) cleavage between threonine and glycine of the LPXTG motif;
and
- b) covalent bonding of the threonine to peptide components of the cell wall, especially the interpeptide bridge.

Thus, the method according to the invention detects both active substances which inhibit the cleavage reaction and thus also prevent the covalent bonding of the polypeptides, and those active substances which possess an inhibitory function in the second step of surface anchoring. As set forth above, these scenarios have been simulated using reporter substances which

had been genetically engineered in a well-aimed manner, and thus the basis of the method according to the invention was created. In addition, the method according to the invention detects also those active substances which have an inhibitory effect on cell wall biosynthesis, e.g., through the inhibition of cell wall biosynthetic enzymes, so that the covalent bonding of polypeptides, especially pathogenicity factors, to the cell wall, especially to interpeptide bridges of the murein sacculus, is no longer possible, or only to a limited extent. In addition, the method according to the invention also detects active substances which release polypeptides already covalently anchored in the cell wall, e.g., through the activation of cell wall hydrolases.

In a preferred embodiment of the method according to the invention, a hybrid polypeptide having a succession, in particular, of the following sequence segments is used as a reporter substance: N-terminal signal peptide, enzyme, sequence segment having the sequence LPXTG, hydrophobic sequence segment, and charged sequence segment. The signal peptide is proteolytically removed in the course of the secretory processing pathway. As shown in the following Examples, *S. hyicus* lipase, in particular, can be used as the enzymatic component of the hybrid polypeptide. However, it may also be of advantage to use *E. coli* β -lactamase or other enzymes. Naturally occurring surface polypeptides as well as genetically engineered hybrid polypeptides may serve as reporter substances which can be detected in the medium due to the action of suitable active substances, using the whole range of known chemical, biochemical and immunological methods. However, in order to ensure a high sample throughput while maintaining the reliability of the method according to the invention, it is advantageous, in particular, to use hybrid polypeptides having enzymatic activity as reporter substances. Thus, those active substances which affect the proteolytic cleavage of the signal peptide as well as the whole transport route through the cytoplasmic membrane do not

result in the appearance of the active reporter substance in the supernatant.

In addition, it may be preferred to use reporter substances having at least one detectable property wherein said reporter substance has an altered detectable property when not covalently bonded to the surface of the Gram-positive bacteria as compared to that exhibited when it is covalently bonded to the surface of the Gram-positive bacteria.

It may further be preferred to provide the enzyme as a proenzyme.

In addition, it may be particularly preferred to determine the change in enzymatic activity due to a transition of the enzyme from an inactive to an active conformation or vice versa. This may preferably be achieved by using a linker peptide provided between the enzyme and the LPXTG motif.

In a preferred embodiment of the method according to the invention, the number of amino acids of the linker peptide is chosen such that the enzyme is anchored to the surface of the Gram-positive bacteria in an inactive conformation. When *S. hyicus* lipase is used, the number of amino acids in the linker peptide should be less than ten, in particular. In another embodiment, the enzyme could be directly fused with its C terminus to the LPXTG motif, avoiding the linker peptide. Thus, in the absence of the active substance, the Gram-positive bacteria bear inactive enzymes covalently bonded to their surface which, when not covalently bonded, especially if released from the surface of the Gram-positive bacteria, fold into an active conformation and thus undergo a detectable change in one of their properties, i.e., enzymatic activity in this case.

It is particularly preferred to perform the method according to the invention with those Gram-positive bacteria which have a

low natural cell wall turnover and/or a small number of cell wall proteases and/or a small number of secreted proteases, in order to minimize the fraction of false positive results in the search for suitable active substances. Thus, the method according to the invention can be performed not only with naturally occurring Gram-positive bacteria, such as *S. carnosus*, but also with bacteria which are already genetically altered.

In addition, it may also be preferred to perform the method according to the invention with Lif expressing cells. Lyso-staphin immunity factor (Lif) expressing Gram-positive cells exhibit modifications in the murein framework of the cell wall. These changes have no influence on the bonding reaction of cellular surface proteins in the cell wall. Example 2 describes a preferred embodiment of the method according to the invention for examining the anchoring of proteins in the cell wall of Lif expressing cells using the exemplary *S. hyicus* lipase or pro-LipFnBPB. The comparison of the enzymatic activity of the lipase on the cell wall and in the supernatant of the culture medium showed that the Lif expression has no influence on the secretion of the lipase or the anchoring of proLipFnBPB in the cellular surface.

In a particularly preferred embodiment of the method according to the invention, the assaying of the enzymatic activity of the reporter substance is done using fluorescence spectroscopy, especially confocal fluorescence spectroscopy, as shown in Example 1. In this case, it is possible to employ the known methods of one- or more-photon excitation. The method of fluorescence correlation spectroscopy (FCS), in particular, as described in detail in WO-A-94/16313, has proven an advantageous assaying method. Instead of the device described in the above mentioned patent application, it may also be preferred to perform FCS using elements of near-field spectroscopy as set forth in DE-C-44 38 391 and the corresponding WO-A-96/13744. These citations are incorporated herein by reference.

WO-A-98/16814 describes a method for the analysis of samples containing particles by repeatedly measuring the number of photons per defined time interval of emitted light or light scattered in the sample, followed by a determination of the distribution function of the number of photons per defined time interval from which the distribution function of particle brightness is then determined. This method can also be preferably employed for the examination of luminescent, especially fluorescent, samples, a specific embodiment in which it is called fluorescence intensity distribution analysis (FIDA). The disclosure of these citations is incorporated herein by reference.

Dyes suitable for fluorescence measurements are known to those skilled in the art from the literature. For example, it may be preferred to determine the conversion of a substrate which undergoes a change in its fluorescence properties. Further, it may be preferred to employ a reporter assay using fluorescent or luminogenic proteins, such as GFP (green fluorescent protein).

In another embodiment of the method according to the invention, it is possible to add groups of possible active substances to the sample of Gram-positive bacteria, and to perform a further differentiation of the group if a positive signal is obtained. In addition, if a possible active substance does not positively interfere with the sample, another possible active substance may be added to the sample without changing the sample. In this case, possible active substances are sequentially added. It is also possible in this case to establish synergistic effects, if the substance which has proven active behaves otherwise in a control experiment than it has behaved in admixture with the apparently inactive substance or substances.

Another embodiment of the method according to the invention detects the anchoring of the reporter substances at the cellu-

lar surface, in addition to assaying their enzymatic activity. This further embodiment of the method according to the invention as described in Example 3 allows to establish whether proteins are prevented from being released by non-covalent bonds. This special embodiment allows to determine in which way the reporter substance is bound to the murein framework. According to Figure 3, muramidase Ch preferably cuts into the cell wall of Gram-positive bacteria so that proteins anchored in the cell wall are cleaved together with cell wall fragments of variable length (Schneewind et al., EMBO J. 12: 4803-4811, 1993). In contrast, non-covalently bonded proteins cleaved by muramidase Ch all have the same molecular weight (Schneewind et al., EMBO J. 12: 4803-4811, 1993). These citations are incorporated herein by reference. According to this particular embodiment, the distinction between the different cleavage products is done by SDS-PAGE (sodium dodecylsulfate polyacrylamide gel electrophoresis) and immunoblotting. For illustrative purposes, the SDS-PAGE running behavior of covalently anchored proteins after release by muramidase Ch and lysostaphin treatment is shown in Figure 4.

In a particularly preferred embodiment of the method according to the invention, distinction can be made in the culture medium as to whether the release of cell wall proteins was caused by the action of substances which affect the anchoring mechanism at the surface of Gram-positive bacteria or by natural changes of the cell wall. In addition to the assaying of the enzymatic activity according to the invention, characterization of the released polypeptides is performed. Example 4 illustrates this with proLipFnBPB from pTX30 and pTX30/pCXlif-expressing cells. ProLipFnBPB released from these cells by natural changes of the cell wall shows an expansion of lipases of different lengths in the gel-electrophoretic examination and subsequent immunoblotting. Instead of an expanded band consisting of a number of overlapping lipase-specific signals, cell wall proteins directly released from the cell, as the proteins obtained by the

action of lysostaphin ($80 \text{ mg} \cdot \text{ml}^{-1}$ in BM, 30 min at 37°C) from the supernatant of non-Lif-expressing cells, show a narrow, sharply bounded band in SDS-PAGE and subsequent immunoblotting.

Figure 1 illustratively describes the structure of a hybrid protein which can be employed as a reporter substance (assay plasmid pTX30Δ82) and the above mentioned structures of the hybrid proteins used for the simulation of the method according to the invention (plasmids pTX30Δ82.sec and pTX30Δ82.mem) in comparison to the structure of *S. hyicus* lipase (plasmid pTX15). At the N terminus, there is located the so-called signal peptide (cross-hatched) which enables the transport of the proenzyme (schematically represented by PP and lipase) through the cytoplasmic membrane and is removed proteolytically in the course of the secretory processing. The lipase is preferably followed by a linker peptide whose length is selected in such a way that the lipase can be anchored at the surface of the Gram-positive bacteria in an inactive conformation. This is followed by the LPETG motif, hydrophobic and charged sequence segments (assay plasmid pTX30Δ82). In the hybrid protein used for simulation (plasmid pTX30Δ82.mem), the LPXTG motif is replaced by the sequence ISQAS. In the hybrid protein used for another simulation (pTX30Δ82.sec), the linker peptide is only followed by a sequence segment of the sequence LPETGG.

Figure 2 shows the quantification of the lipase activity in the simulations clones. The respective lipase activity in the culture supernatant was determined in relation to the total activity of the respective clone.

Figure 3 shows the structure of the peptidoglycane in *Staphylococci* with a C-terminally linked surface protein. The cleavage sites for muramidase Ch and lysostaphin are highlighted.

Figure 4 represents the influence of lysostaphin on the cellular surface proteins which were released from the cell wall of

S. carnosus by muramidase Ch. ProLipFnBPB was synthesized in these cells in the presence (+) or absence (-) of Lif (pCXLif). The released hybrid proteins were incubated in the presence (+) or absence (-) of lysostaphin and subsequently characterized by SDS-PAGE (10% acrylamide) and immunoblotting (prolipase-specific antiserum) according to Strauß and Götz (Mol. Microbiol. 21: 491-500, 1996). The molecular weight of the protein standards (in kDa) is given on the left margin.

Figure 5 shows the influence of lysostaphin on proLipFnBPB which was released from *S. carnosus* into the culture medium by natural cell wall changes.

Supernatants of cells expressing proLipFnBPB (pTX30) in the presence (+) or absence (-) of Lif (pCXLif) were examined in the presence (+) or absence (-) of lysostaphin. As the reference, there was used proLipFnBPB released by the action of lysostaphin from the cell wall of *S. carnosus* cells which only contained the plasmid pTX30. The proteins were separated by SDS-PAGE (10% acrylamide), and immunoblotting (prolipase-specific antiserum) was performed. The molecular weights of the standard molecules are given on the left margin.

Example 1

Simulation scenarios

Strains and plasmids

The wild type strain *S. carnosus* TM300 (Götz, F., J. Appl. Bacteriol. Symp. Supp. 69: 49-53, 1990) was used as the host organism for the production of all recombinant *Staphylococcus* strains. The preparation of the assay plasmid pTX30Δ82 is described in the following:

The plasmid pTX30Δ82 was prepared by analogy with the plasmid pCX30Δ82 (Strauß and Götz, Mol. Microbiol. 21: 491-500, 1996). However, rather than the chloramphenicol selectable plasmid pCX15 (Wieland et al., Gene 158: 91-96, 1995), the tetracyclin selectable plasmid pTX15 (Peschel et al., FEMS Microbiol. Lett. 137: 279-284, 1996) was used as the starting vector. This plasmid contains a gene fusion which encodes the assay hybrid protein (proLipFnBPBΔ82) consisting of *S. hyicus* lipase and the C-terminal portion of the fibronectin binding protein B (FnBPB) and which is under the control of the inducible xylose promoter (Wieland et al., Gene 158: 91-96, 1995). The distance between the C-terminal alanine residue of the lipase and the leucine residue of the LPXTG motif of FnBPB was 10 amino acids (Figure 1).

The plasmids pTX30Δ82.mem and pTX30Δ82.sec were prepared by analogy with the plasmid pTX30Δ82 using the oligonucleotide pairs (SEQ. ID. NOS. 2 to 5) AS14 (5'-ATAAGGCGCCTTAGTTTAATTATGCTTTGTGATTC)/AS45 (5'-CGCAGGAAGCTT-ACCACAATCTAAGAAATCTGAAATATCTCAAGCAAGTGGAGAAG) and AS42 (5'-AATAAGGCGCCTCATTATCCACCTGTTTCAGGTAGTTC)/AS22 (5'-ACGAAAGCT-TACCACAATCTAAGAAATCTGAAC), starting with pTX30. The plasmids pTX30Δ82, pTX30Δ82.mem and pTX30Δ82.sec were transformed into *S. carnosus* TM300 (Götz and Schumacher, FEMS Microbiol. Lett. 40: 285-288, 1987). The citations mentioned are incorporated herein by reference.

Media

For culturing the bacteria in liquid culture, basal medium (BM) was used which contained 1% peptone, 0.5% yeast extract, 0.5% NaCl, 0.1% glucose and 0.1% dipotassium hydrogenphosphate (pH 7.4). For the induction of the xylose promoter, modified basal medium (induction medium) was used in which the glucose had been replaced by 0.5% xylose. According to need, chloramphenicol (Cm, 10 mg/l), tetracyclin (Tc, 25 mg/l) and erythromycin (Em, 2.5 mg/l) was added to the BM. Agar selection plates were

supplemented with 15 g/l agar. Lipase test plates were prepared using tributyrin-agar base (Merck) according to the supplier's instructions. Prior to casting the plates, 1% glycerol tributyrate and the corresponding antibiotics (Tc, Em) were added to the agar. On these plates, lipase-releasing bacterial cells can be identified by the formation of clear halos.

Part I: Localization and Quantification of lipase activity in the simulation clones

5 ml each of basal medium were inoculated from a plate with the wild type strain *S. carnosus* TM300 or the above described *S. carnosus* clones and incubated at 37 °C over night with shaking. With these precultures, 5 ml each of induction medium was inoculated at 1:100 and shaken at 37 °C until the late logarithmic growth stage was reached. The cultures were cooled to 4 °C prior to determining the lipase activity in the culture supernatant and the cell-bound lipase activity after release by treating the cells with lysostaphin according to Strauß and Götz (Mol. Microbiol. 21: 491-500, 1996). The total activity was obtained as the sum of the cell-bound activity and the activity in the culture supernatant. Subsequently, the respective lipase activity in the culture supernatant was determined in relation to the total activity of the corresponding clone (Figure 2). This citation is incorporated herein by reference.

Part II: Establishing of a fluorescence-spectroscopy based assay method

The *S. carnosus* clones *S. carnosus*/pTX30Δ82, /pTX30Δ82.mem and /pTX30Δ82.sec were cultured over night at 37 °C in basal medium. The cell densities of these cultures were determined by measuring the optical densities (OD576) in a photometer, and dilutions (about 1:200) of equal cell densities were prepared. For preparing these dilutions, modified basal medium (induction medium) was used. Then, the diluted cultures were again allowed

to grow at 37 °C. In various experiments, both microtitration plates and other vessels were used for the cultures.

At different times of cultivation, the lipase activity released by the bacteria was determined in the culture supernatants. The cells were pelleted by centrifugation, the culture supernatants were taken off and, if necessary, stored on ice. Assays were performed in microtitration plates (100 µl) with glass bottoms. The lipase assay buffer was constituted as follows: 10 mM CaCl₂, 0.05% Triton X-100, 20 mM Tris/HCl, pH 8.0. As the fluorogenic dye substrate, 1,2-o-dilauryl-rac-glycero-3-glutaric acid resorufin ester (Sigma # D7414) was used. The substrate stock solution was prepared in 100% DMSO at 1 mg/ml and stored at -20 °C. Per measuring sample, 10 µl each of the culture supernatants was mixed with 80 µl lipase assay buffer and 10 µl substrate solution (10 µM final concentration). The conversion of the substrate was determined by fluorometry using a fluorescence (ELISA) reader, or by means of a fluorescence correlation spectrometer, such as ConfoCor™ (Carl Zeiss, Jena, and Evotec, Germany).

While clone *S. carnosus*/pTX30Δ82 gave insignificantly higher signals than those from the negative control (only buffer and substrate) in the measurements, significant amounts of lipase activity were found in the culture supernatants of the two clones *S. carnosus*/pTX30Δ82.mem and *S. carnosus*/pTX30Δ82.sec.

Example 2

Strains and plasmids

The citations stated in the following are incorporated herein by reference.

The wild type strain *S. carnosus* TM300 (Götz, F., J. Appl. Bacteriol. Symp. Supp. 69: 49-53, 1990) was used as the host

organism for the production of all recombinant *Staphylococcus* strains. The plasmids pTX15, pTX30 (encodes ProLipFnBPB, a hybrid protein consisting of *S. hyicus* lipase linked to the C terminus of *S. aureus* fibronectin binding protein B) and pCXlif (lif, lysostaphin immunity factor) were transformed into *S. carnosus* TM300 as described by Götz and Schumacher (FEMS Microbiol. Lett. 40: 285-288, 1987).

The construction of pCXlif was effected according to the method described by Thumm and Götz (Mol. Microbiol. 23: 1251-1256, 1997).

The plasmid pTX30 was prepared by insertion of the BamHI-NarI fragment of pCX30 (Strauß and Götz, Mol. Microbiol. 21: 491-500, 1996) into the plasmid pTX15 cut with the same restriction enzymes.

The genes were expressed under the control of the xylose promoter system (Wieland et al., Gene 158: 91-96, 1995). The induction of the expression was effected as described by Strauß and Götz (Mol. Microbiol. 21: 491-500, 1996).

The sequences of the nucleic acids used herein have been deposited with gene banks as follows: gene bank entry number: plasmid pT181: g151679; xylR (*S. xylosus*): g48833; lip (*S. hyicus*): g488333; plasmid pC194: g150548; fnbB (*S. aureus*): g49040.

Media

The bacteria were cultured in basal medium (BM; see Example 1) at 30 °C. According to need, chloramphenicol (Cm, 10 mg/l) or tetracyclin (Tc, 25 mg/l) was added to the basal medium.

The influence of the lysostaphin immunity factor (Lif) on the secretion and anchoring of *S. hyicus* lipase or proLipFnBPB in the cell wall by comparing the lipase activities on the cell wall and in the supernatant of the culture medium.

The cell cultures (pTX15, pTX30, pTX15+pCXlif, pTX30+pCXlif) were first separated into cell pellets and medium by centrifugation. Then, the pellets were washed three times with BM and taken up in BM. Cell wall proteins released from pTX30 expressing cells by treatment with lysostaphin (80 µg/ml in BM; 30 min at 37 °C) served as the reference. Dilutions from the samples were made. Thus, 95 µl of lipase assay buffer (10 mM CaCl₂, 0.1% Triton X-100 and 20 mM Tris-HCl, pH 8.5) containing the chromogenic lipase substrate p-nitrophenyl caprylate [Sigma] in a concentration of 5 mM was added to 5 µl each of the culture supernatants. The hydrolysis of the substrate was subsequently followed over 10 minutes at 30 °C photometrically using a microtitration plate (ELISA) reader (SpectraMax, Molecular Devices) or by means of fluorescence correlation spectroscopy with ConfoCor at a wavelength of 405 nm. The assays were performed in microtitration plates with or without a glass bottom.

All in all, it was found that the total lipase activity in the supernatant was 99.2% for cells expressing pXT15, and 99.1% in cells expressing both pXT15 and pCXlif. Cells containing pTX30 served as a control for the anchoring of the lipase in the cell wall. In contrast to, e.g., pTX30A82 encoded proLipFnBPBA82 (see Example 1), the pTX30 encoded proLipFnBPB is enzymatically active when anchored in the cell wall. In these cells, the total lipase activity at the cellular surface was around 85.1%, as in cells which expressed both pTX30 and pCXlif (84.5%).

Thus, it could be shown that Lif expression has no influence on the secretion of lipase or the anchoring of proLipFnBPB in the cellular surface.

Example 3

Strains and plasmids

The strains and plasmids used are those mentioned in Example 2.

Media

The bacteria were cultured in basal medium (BM; see Example 1) at 30 °C. According to need, chloramphenicol (Cm, 10 mg/l) or tetracyclin (Tc, 25 mg/l) was added to the basal medium.

Determination of the enzymatic activity of the released proteins

The lipase activity released by the bacteria was determined in the culture supernatants as follows:

The cells were sedimented by centrifugation, the culture supernatants were taken off and, if necessary, stored on ice. Assays were performed in microtitration plates without a glass bottom. The lipase assay buffer (10 mM CaCl₂, 0.1% Triton X-100 and 20 mM Tris/HCl, pH 8.5) contained the chromogenic lipase substrate p-nitrophenyl caprylate [Sigma] in a concentration of 5 mM. Per measuring sample, 5 µl each of the culture supernatants was mixed with 95 µl lipase assay buffer. The conversion of the substrate was determined by photometry using a microtitration plate (ELISA) reader.

Distinction between proteins which are covalently or non-covalently bonded to the cell wall

In order to exclude that any proLipFnBPB is non-covalently bonded to the cell wall of the expressing cells and for this reason is not covered in the determination of the enzymatic activity in the supernatant, a strategy has been developed

which is based on the use of muramidase Ch and lysostaphin. Muramidase Ch hydrolyzes the β -1,4-linkage of N-acetylmuramic acid and acetylglucosamine (Figure 3) (Ghuysen, Bacteriol. Rev. 32: 425-464, 1968). It does not cut directly at the linkage sites of the surface proteins to the cell wall so that the proteins are cleaved together with cell wall fragments of variable lengths (Schneewind et al., EMBO J. 12: 4803-4811, 1993). In contrast, non-covalently bonded proteins cleaved by muramidase Ch all have the same molecular weight (Schneewind et al., EMBO J. 12: 4803-4811, 1993). The citations mentioned are incorporated herein by reference.

The cells were obtained from 500 μ l culture medium by centrifugation. Then, the pellets were washed three times with water and precipitated by adding trichloroacetic acid (7% w/v) (20 min on ice). After centrifuging the precipitate, the pellet formed was washed twice with acetone and dried in vacuo. The pellets were then dissolved in 170 μ l BM to which muramidase Ch (100 μ g \cdot ml⁻¹) had been added, and the solution was incubated at 37 °C for 3 h. Then, the samples were again centrifuged, and the supernatant was divided into two aliquots of 80 μ l each; 20 μ l of water was added to one of them, and 20 μ l of lysostaphin solution (400 mg \cdot ml⁻¹) was added to the other. The solutions were incubated at 37 °C for 30 min. The individual aliquots were then concentrated and examined using SDS-PAGE (10% acrylamide) and immunoblotting (with prolipase-specific antiserum).

It was found (Figure 4) that muramidase Ch results in complete release of proLipFnBPB from the cell wall of *S. carnosus*, irrespective of whether or not Lif (pCXlif) was also expressed in these cells. In both cases, a spectrum of lipase-specific signals could be seen on the gel as an expansion which is due to cell wall fragments of different lengths covalently bonded to proLipFnBPB.

For the discrimination of Lif-expressing cells, the samples were treated with lysostaphin in a parallel run prior to performing the gel electrophoresis and the immunoblotting. It was found that in the cases in which proLipFnBPB was released from cells which did not express Lif, the residues of the cell wall anchoring were completely removed. On the gel, this could be seen as a sharp band. Surface proteins derived from Lif-expressing cells were not lysostaphin-sensitive (Figure 4).

Example 4

Strains and plasmids

The strains and plasmids used are those mentioned in Example 2.

Media

The bacteria were cultured in basal medium (BM; see Example 1) at 30 °C. According to need, chloramphenicol (Cm, 10 mg/l) or tetracyclin (Tc, 25 mg/l) was added to the basal medium.

Determination of the enzymatic activity of the released proteins

The lipase activity released by the bacteria was determined in the culture supernatants in accordance with Example 3.

Determination of the fraction of surface proteins released from S. carnosus by natural cell wall changes

One important characteristic of cell wall proteins released by natural cell wall changes is being covalently bonded to the cell wall prior to the release. For determining the fraction of naturally released proteins, the culture supernatant of cells containing the plasmids pCXLif and/or pTX30 is concentrated and analyzed by SDS-PAGE and immunoblotting. proLipFnBPB released

by lysostaphin from cells which only contained the plasmid pTX30 was used as the reference. In addition to decomposition products which had a greater electrophoretic mobility than that of the reference, a number of overlapping lipase-specific signals were observed as an expansion. Incubation of the supernatant with lysostaphin ($80 \text{ mg} \cdot \text{ml}^{-1}$ in BM, 30 min at 37°C) prior to gel electrophoresis and immunoblotting had an effect only on those proteins which had been obtained from the supernatant of non-Lif-expressing cells. Instead of the expansion of a number of overlapping lipase-specific signals, a limited band can be seen which exhibits the same electrophoretic mobility as the reference. The lipase-specific signals derived from cells which express Lif and proLipFnBPS are not affected by lysostaphin.

In this study, it was found, in addition, that a total of 5% of the total lipase activity of cells expressing ProLipFnBPS by low-copy number plasmids, was measured in the supernatant from natural release whereas even 15% of the total lipase activity could be determined in the supernatant for medium-copy number plasmids. The coexpression of other surface proteins had no influence on the release of lipase.

C L A I M S :

1. A method for identifying active substances which affect the covalent bonding of polypeptides to the surface of Gram-positive bacteria, comprising the following steps:
 - a) providing a sample of Gram-positive bacteria which contain or produce at least one enzymatic reporter substance which is or can become covalently bonded to the surface of the Gram-positive bacteria, said at least one reporter substance having a different enzymatic activity when not covalently bonded to the surface of the Gram-positive bacteria from that exhibited when it is covalently bonded to the surface of the Gram-positive bacteria;
 - b) contacting the sample with a possible active substance; and
 - c) assaying the enzymatic activity of the reporter substance of the Gram-positive bacteria of the sample.
2. The method according to claim 1, characterized in that said assaying of the enzymatic activity of the reporter substance is done by comparison with at least one reference sample which has not been genetically altered, and/or at least one reference sample in which the reporter substance is non-covalently bonded to the surface of Gram-positive bacteria, and/or at least one reference sample in which the reporter substance is covalently bonded to the surface of the Gram-positive bacteria, and/or at least one reference sample in which the reporter substance is pres-

ent without covalent bonding to the surface of the Gram-positive bacteria.

3. The method according to claims 1 and/or 2, characterized in that said covalent bonding of the polypeptides is effected to the murein of the cell wall, especially at interpeptide bridges, such as pentaglycines, of Gram-positive bacteria.
4. The method according to at least one of claims 1 to 3, characterized in that said polypeptides are pathogenicity factors of Gram-positive bacteria.
5. The method according to at least one of claims 1 to 4, characterized in that said reporter substance is a hybrid polypeptide.
6. The method according to claim 5, characterized in that said hybrid polypeptide has a succession of the following sequence segments: N-terminal signal peptide, enzyme, sequence segment having the sequence LPXTG, hydrophobic sequence segment, and charged sequence segment.
7. The method according to claim 6, characterized in that said enzyme is provided as a proenzyme.
8. The method according to at least one of claims 6 to 7, characterized in that said change of enzymatic activity is due to a transition of the enzyme from an inactive to an active conformation or vice versa.
9. The method according to claim 6 to 8, characterized in that a linker peptide, especially one comprising less than 10 amino acids, is provided between said enzyme and said sequence segment having the sequence LPXTG.

10. The method according to at least one of claims 1 to 9, characterized in that said Gram-positive bacteria have a low natural cell wall turnover and/or a small number of cell wall proteases and/or a small number of secreted proteases.
11. The method according to at least one of claims 1 to 10, characterized in that said assaying of the enzymatic activity of said at least one reporter substance is done using fluorescence spectroscopy, especially confocal fluorescence spectroscopy.
12. The method according to at least one of claims 1 to 11, characterized in that said Gram-positive bacteria express Lif.
13. The method according to at least one of claims 1 to 12, characterized in that the fraction of reporter substances released by natural cell wall changes is determined.
14. The method according to at least one of claims 1 to 13, characterized in that the fraction of reporter substances which are non-covalently bonded to the surface of Gram-positive bacteria is determined.

A b s t r a c t

A method for identifying active substances which affect the covalent bonding of polypeptides to the surface of Gram-positive bacteria, comprising the following steps:

- a) providing a sample of Gram-positive bacteria which contain or produce at least one enzymatic reporter substance which is or can become covalently bonded to the surface of the Gram-positive bacteria, said at least one reporter substance having a different enzymatic activity when not covalently bonded to the surface of the Gram-positive bacteria from that exhibited when it is covalently bonded to the surface of the Gram-positive bacteria;
- b) contacting the sample with a possible active substance; and
- c) assaying the enzymatic activity of the reporter substance of the Gram-positive bacteria of the sample.




Figure 1




Figure 2




Figure 3

- 4/5 -




Figure 4

- 5/5 -




Figure 5

DECLARATION
AND POWER OF ATTORNEY
U.S.A.

FOR ATTORNEYS' USE ONLY

ATTORNEYS' DOCKET NO. 1/4

ALL PATENTS, INCLUDING DESIGN

FOR APPLICATION BASED ON PCT, PARIS CONVENTION,

NON PRIORITY; OR PROVISIONAL APPLICATIONS

As a below named inventor, I declare that my residence, post office address and citizenship are stated below next to my name, the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed at 201 below), or an original, first and joint inventor (if plural inventors are named below at 201-203, or on additional sheets attached hereto) of the subject matter which is claimed and for which patent is sought on the invention entitled

A method for identifying active substance

which is described and claimed in: ☒ PCT International Application No PCT/EP 98/06137 filed 26/09/1998

☐ the attached specification

☐ the specification in application Serial No. _____

filed _____

(if applicable) and amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

97 116 840.6

(Number)

Europe

(Country)

27/09/1997

(Day/Month/Year Filed)

Priority Claimed

☒ Yes

☐ No

97 118 756.2

(Number)

Europe

(Country)

29/10/1997

(Day/Month/Year Filed)

☒ Yes

☐ No

(Number)

(Country)

(Day/Month/Year Filed)

☐ Yes

☐ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Application No. _____

Filing Date _____

Application No. _____

Filing Date _____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status: patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys (Registration No.) to prosecute this application, receive and act on instructions from my agent, and transact all business in the Patent and Trademark Office connected therewith. HARVEY B. JACOBSON, JR. (20,851); D. DOUGLAS PRICE (24,514); JOHN CLARKE HOLMAN (22,769); MARVIN R. STERN (20,640); MICHAEL R. SLOBASKY (26,421); JONATHAN L. SCHERER (29, 851); IRWIN M. AISENBERG (19,007); WILLIAM E. PLAYER (31,409).

SEND CORRESPONDENCE TO:

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY
400 Seventh Street, N.W.
Washington, D.C. 20004

DIRECT TELEPHONE CALLS TO:

(please use Attorney's Docket No.) (202) 638-6666

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY

Inventor(s) name must include at least one unabbreviated first or middle name.

201	FULL NAME* OF INVENTOR	FAMILY NAME <u>STRAUSS</u>	GIVEN NAME <u>Andreas</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Hamburg</u>	STATE OR FOREIGN COUNTRY <u>Germany</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>
	POST OFFICE ADDRESS	<u>Schnackenburgallee 114</u>	CITY <u>Hamburg</u>	STATE OR COUNTRY <u>Germany</u> ZIP CODE <u>D-22525</u>
202	FULL NAME* OF INVENTOR	FAMILY NAME <u>THUMM</u>	GIVEN NAME <u>Günther</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Hamburg</u>	STATE OR FOREIGN COUNTRY <u>Germany</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>
	POST OFFICE ADDRESS	<u>Schnackenburgallee 114</u>	CITY <u>Hamburg</u>	STATE OR COUNTRY <u>Germany</u> ZIP CODE <u>D-22525</u>
203	FULL NAME* OF INVENTOR	FAMILY NAME <u>POHLNER</u>	GIVEN NAME <u>Johannes</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Hamburg</u>	STATE OR FOREIGN COUNTRY <u>Germany</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>
	POST OFFICE ADDRESS	<u>Schnackenburgallee 114</u>	CITY <u>Hamburg</u>	STATE OR COUNTRY <u>Germany</u> ZIP CODE <u>D-22525</u>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201*	SIGNATURE OF INVENTOR 202*	SIGNATURE OF INVENTOR 203*
<u>X</u> <u>Andreas Strauss</u>		
DATE <u>X</u> <u>12/15/99</u>	DATE	DATE

☐ Additional inventors are named on separately numbered sheets attached hereto.

© JPH&S 1995 8/95; 3/97 (COPYING WITHOUT DELETIONS PERMITTED)

JACOBSON, PRICE, HOLMAN & STERN
ADDITIONAL INVENTORS

* Inventor(s) name must include at least one unabbreviated first or middle name

204	FULL NAME * OF INVENTOR	FAMILY NAME GÖTZ	GIVEN NAME Friedrich	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY Hamburg	STATE OR FOREIGN COUNTRY Germany	COUNTRY OF CITIZENSHIP Germany	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS Schnackenburgallee 114	CITY Hamburg	STATE OR COUNTRY Germany	ZIP CODE D-22525
205	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
207	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
208	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
209	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
210	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
211	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 204*	SIGNATURE OF INVENTOR 205*	SIGNATURE OF INVENTOR 206*
DATE	DATE	DATE
SIGNATURE OF INVENTOR 207*	SIGNATURE OF INVENTOR 208*	SIGNATURE OF INVENTOR 209*
DATE	DATE	DATE
SIGNATURE OF INVENTOR 210*	SIGNATURE OF INVENTOR 211*	
DATE	DATE	

☐ Additional inventors are named on separately numbered sheets attached hereto.
 ©JPH&S 1995 8/95 (COPYING WITHOUT DELETIONS PERMITTED)

DECLARATION
AND POWER OF ATTORNEY
U.S.A.

FOR ATTORNEYS' USE ONLY

ATTORNEYS' DOCKET NO. 2/4

ALL PATENTS, INCLUDING DESIGN

FOR APPLICATION BASED ON PCT, PARIS CONVENTION;

NON PRIORITY; OR PROVISIONAL APPLICATIONS

As a below named inventor, I declare that my residence, post office address and citizenship are stated below next to my name, the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed at 201 below), or an original, first and joint inventor (if plural inventors are named below at 201-203, or on additional sheets attached hereto) of the subject matter which is claimed and for which patent is sought on the invention entitled:

A method for identifying active substance

which is described and claimed in: ☒ PCT International Application No. PCT/EP 98/06137 filed 26/09/1998

☐ the attached specification

☐ the specification in application Serial No. _____

filed _____

(if applicable) and amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

97 116 840.6

(Number)

Europe

(Country)

27/09/1997

(Day/Month/Year Filed)

Priority Claimed

☒ Yes

☐ No

97 118 756.2

(Number)

Europe

(Country)

29/10/1997

(Day/Month/Year Filed)

☒ Yes

☐ No

(Number)

(Country)

(Day/Month/Year Filed)

☐ Yes

☐ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Application No. _____

Filing Date _____

Application No. _____

Filing Date _____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status: patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys (Registration No.) to prosecute this application, receive and act on instructions from my agent, and transact all business in the Patent and Trademark Office connected therewith. HARVEY B. JACOBSON, JR. (20,851); D. DOUGLAS PRICE (24,514); JOHN CLARKE HOLMAN (22,769); MARVIN R. STERN (20,640); MICHAEL R. SLOBASKY (26,421); JONATHAN L. SCHERER (29, 851); IRWIN M. AISENBERG (19,002); WILLIAM E. PLAYER (31,409)

SEND CORRESPONDENCE TO:

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY
400 Seventh Street, N.W.
Washington, D.C. 20004

DIRECT TELEPHONE CALLS TO:

(please use Attorney's Docket No.) (202) 638-6666

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY

*Inventor(s) name must include at least one unabbreviated first or middle name.

201	FULL NAME* OF INVENTOR	FAMILY NAME <u>STRAUSS</u>	GIVEN NAME <u>Andreas</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Hamburg</u>	STATE OR FOREIGN COUNTRY <u>Germany</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Schnackenburgallee 114</u>	CITY <u>Hamburg</u>	STATE OR COUNTRY <u>Germany</u> ZIP CODE <u>D-22525</u>
202	FULL NAME* OF INVENTOR	FAMILY NAME <u>THUMM</u>	GIVEN NAME <u>Günther</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Hamburg</u>	STATE OR FOREIGN COUNTRY <u>Germany</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Schnackenburgallee 114</u>	CITY <u>Hamburg</u>	STATE OR COUNTRY <u>Germany</u> ZIP CODE <u>D-22525</u>
203	FULL NAME* OF INVENTOR	FAMILY NAME <u>POHLNER</u>	GIVEN NAME <u>Johannes</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Hamburg</u>	STATE OR FOREIGN COUNTRY <u>Germany</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Schnackenburgallee 114</u>	CITY <u>Hamburg</u>	STATE OR COUNTRY <u>Germany</u> ZIP CODE <u>D-22525</u>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201*	SIGNATURE OF INVENTOR 202*	SIGNATURE OF INVENTOR 203*
DATE	DATE <u>16.11.1999</u>	DATE

☐ Additional inventors are named on separately numbered sheets attached hereto.

© JPH&S 1995 8/95; 3/97 (COPYING WITHOUT DELETIONS PERMITTED)

JACOBSON, PRICE, HOLMAN & STERN
ADDITIONAL INVENTORS

* Inventor(s) name must include at least one unabbreviated first or middle name.

204	FULL NAME * OF INVENTOR	FAMILY NAME GÖTZ	GIVEN NAME Friedrich	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY Hamburg	STATE OR FOREIGN COUNTRY Germany	COUNTRY OF CITIZENSHIP Germany	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS Schnackenburgallee 114	CITY Hamburg	STATE OR COUNTRY Germany	ZIP CODE D-22525
205	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
207	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
208	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
209	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
210	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
211	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 204*	SIGNATURE OF INVENTOR 205*	SIGNATURE OF INVENTOR 206*
DATE	DATE	DATE
SIGNATURE OF INVENTOR 207*	SIGNATURE OF INVENTOR 208*	SIGNATURE OF INVENTOR 209*
DATE	DATE	DATE
SIGNATURE OF INVENTOR 210*	SIGNATURE OF INVENTOR 211*	
DATE	DATE	

☐ Additional inventors are named on separately numbered sheets attached hereto.
©JPH&S 1995 8/95 (COPYING WITHOUT DELETIONS PERMITTED)

DECLARATION
AND POWER OF ATTORNEY
U.S.A.

FOR ATTORNEYS' USE ONLY

3/4

ATTORNEYS' DOCKET NO.

ALL PATENTS, INCLUDING DESIGN

FOR APPLICATION BASED ON PCT, PARIS CONVENTION;

NON PRIORITY, OR PROVISIONAL APPLICATIONS

As a below named inventor, I declare that my residence, post office address and citizenship are stated below next to my name, the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed at 201 below), or an original, first and joint inventor (if plural inventors are named below at 201-203, or on additional sheets attached hereto) of the subject matter which is claimed and for which patent is sought on the invention entitled:

A method for identifying active substance

which is described and claimed in: ☒ PCT International Application No. PCT/EP 98/06137 filed 26/09/1998

☐ the attached specification ☐ the specification in application Serial No. _____ filed _____
(if applicable) and amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

97 116 840.6

(Number)

Europe

(Country)

27/09/1997

(Day/Month/Year Filed)

Priority Claimed

☒ Yes

☐ No

97 118 756.2

(Number)

Europe

(Country)

29/10/1997

(Day/Month/Year Filed)

☒ Yes

☐ No

(Number)

(Country)

(Day/Month/Year Filed)

☐ Yes

☐ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Application No. _____ Filing Date _____ Application No. _____ Filing Date _____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status: patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys (Registration No.) to prosecute this application, receive and act on instructions from my agent, and transact all business in the Patent and Trademark Office connected therewith. HARVEY B. JACOBSON, JR. (20,851); D. DOUGLAS PRICE (24,514); JOHN CLARKE HOLMAN (22,769); MARVIN R. STERN (20,640); MICHAEL R. SLOBASKY (26,421); JONATHAN SCHERER (29, 851); IRWIN M. AISENBERG (19,007); WILLIAM E. PLAYER (31,409)

SEND CORRESPONDENCE TO:

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY
400 Seventh Street, N.W.
Washington, D.C. 20004

DIRECT TELEPHONE CALLS TO:

(please use Attorney's Docket No.) (202) 638-6666

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY

Inventor(s) name must include at least one unabbreviated first or middle name.

201	FULL NAME* OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY
202	FULL NAME* OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY
203	FULL NAME* OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201*	SIGNATURE OF INVENTOR 202*	SIGNATURE OF INVENTOR 203*
DATE	DATE	DATE

☐ Additional inventors are named on separately numbered sheets attached hereto.

© JPH&S 1995 8/95; 3/97 (COPYING WITHOUT DELETIONS PERMITTED)

JACOBSON, PRICE, HOLMAN & STERN
ADDITIONAL INVENTORS

* Inventor(s) name must include at least one unabbreviated first or middle name

204	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
		GÖTZ	Friedrich		
		Hamburg	Germany	Germany	
		Schnackenburgallee 114	Hamburg	Germany	D-22525
205	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
207	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
208	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
209	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
210	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
211	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 204*	SIGNATURE OF INVENTOR 205*	SIGNATURE OF INVENTOR 206*
DATE	DATE	DATE
SIGNATURE OF INVENTOR 207*	SIGNATURE OF INVENTOR 208*	SIGNATURE OF INVENTOR 209*
DATE	DATE	DATE
SIGNATURE OF INVENTOR 210*	SIGNATURE OF INVENTOR 211*	
DATE	DATE	

☐ Additional inventors are named on separately numbered sheets attached hereto
 OJPH&S 1995 8/95 (COPYING WITHOUT DELETIONS PERMITTED)

DECLARATION
AND POWER OF ATTORNEY
U.S.A.

FOR ATTORNEYS' USE ONLY

ATTORNEYS' DOCKET NO. 44

ALL PATENTS, INCLUDING DESIGN

FOR APPLICATION BASED ON PCT, PARIS CONVENTION;

NON PRIORITY; OR PROVISIONAL APPLICATIONS

As a below named inventor, I declare that my residence, post office address and citizenship are stated below next to my name, the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed at 201 below), or an original, first and joint inventor (if plural inventors are named below at 201-203, or on additional sheets attached hereto) of the subject matter which is claimed and for which patent is sought on the invention entitled:

A method for identifying active substance

which is described and claimed in: ☒ PCT International Application No. PCT/EP 98/06137 filed 26/09/1998

☐ the attached specification

☐ the specification in application Serial No. _____ filed _____

(if applicable) and amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

97 116 840.6

(Number)

Europe

(Country)

27/09/1997

(Day/Month/Year Filed)

Priority Claimed

☒ Yes ☐ No

97 118 756.2

(Number)

Europe

(Country)

29/10/1997

(Day/Month/Year Filed)

☒ Yes ☐ No

(Number)

(Country)

(Day/Month/Year Filed)

☐ Yes ☐ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Application No. _____ Filing Date _____ Application No. _____ Filing Date _____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status: patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys (Registration No.) to prosecute this application, receive and act on instructions from my agent, and transact all business in the Patent and Trademark Office connected therewith. HARVEY B. JACOBSON, JR. (20,851); D. DOUGLAS PRICE (24,514); JOHN CLARKE HOLMAN (22,769); MARVIN R. STERN (20,640); MICHAEL R. SLOBASKY (26,421); JONATHAN L. SCHERER (29, 851); IRWIN M. AISENBERG (19,007); WILLIAM E. PLAYER (31,409).

SEND CORRESPONDENCE TO:

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY
400 Seventh Street, N.W.
Washington, D.C. 20004

DIRECT TELEPHONE CALLS TO:

(please use Attorney's Docket No.) (202) 638-6666

JACOBSON, PRICE, HOLMAN & STERN
PROFESSIONAL LIMITED LIABILITY COMPANY

*Inventor(s) name must include at least one unabbreviated first or middle name.

201	FULL NAME* OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY
202	FULL NAME* OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY
203	FULL NAME* OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201*	SIGNATURE OF INVENTOR 202*	SIGNATURE OF INVENTOR 203*
DATE	DATE	DATE

☐ Additional inventors are named on separately numbered sheets attached hereto.

© JPH&S 1995 8/95; 3/97 (COPYING WITHOUT DELETIONS PERMITTED)

FOURTH INVENTOR'S
SIGNATURE

JACOBSON, PRICE, HOLMAN & STERN
ADDITIONAL INVENTORS

* Inventor(s) name must include at least one unabbreviated first or middle name

204	FULL NAME * OF INVENTOR	FAMILY NAME <u>GÖTZ</u>	GIVEN NAME <u>Friedrich</u>	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY <u>Hamburg</u>	STATE OR FOREIGN COUNTRY <u>Germany</u> <i>DEX</i>	COUNTRY OF CITIZENSHIP <u>Germany</u>	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Schnackenburgallee 114</u>	CITY <u>Hamburg</u>	STATE OR COUNTRY <u>Germany</u>	ZIP CODE <u>D-22525</u>
205	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
207	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
208	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
209	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
210	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
211	FULL NAME * OF INVENTOR	FAMILY NAME	GIVEN NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 204*	SIGNATURE OF INVENTOR 205*	SIGNATURE OF INVENTOR 206*
DATE X	DATE	DATE
SIGNATURE OF INVENTOR 207*	SIGNATURE OF INVENTOR 208*	SIGNATURE OF INVENTOR 209*
DATE	DATE	DATE
SIGNATURE OF INVENTOR 210*	SIGNATURE OF INVENTOR 211*	
DATE	DATE	

☐ Additional inventors are named on separately numbered sheets attached hereto
©JPH&S 1995 8/95 (COPYING WITHOUT DELETIONS PERMITTED)